Haemonetics Co. (NYSE:HAE) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its position in Haemonetics Co. (NYSE:HAE - Free Report) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 386,489 shares of the medical instruments supplier's stock after selling 15,785 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.77% of Haemonetics worth $30,177,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of HAE. Wellington Management Group LLP grew its holdings in shares of Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier's stock valued at $337,722,000 after purchasing an additional 363,702 shares in the last quarter. Royce & Associates LP boosted its position in Haemonetics by 2.6% in the 3rd quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier's stock valued at $97,304,000 after buying an additional 30,868 shares during the period. Geode Capital Management LLC grew its stake in shares of Haemonetics by 1.8% in the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock worth $95,986,000 after acquiring an additional 21,547 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Haemonetics by 29.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier's stock worth $88,433,000 after acquiring an additional 250,833 shares during the period. Finally, Boston Trust Walden Corp raised its stake in shares of Haemonetics by 13.1% in the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock valued at $71,500,000 after acquiring an additional 106,114 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

HAE has been the subject of several analyst reports. Needham & Company LLC lowered their target price on Haemonetics from $112.00 to $108.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Finally, Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Haemonetics currently has an average rating of "Moderate Buy" and an average price target of $101.67.

Haemonetics Stock Down 3.6 %

Shares of Haemonetics stock traded down $2.47 during trading hours on Wednesday, hitting $65.83. The company had a trading volume of 529,726 shares, compared to its average volume of 1,003,232. The company's 50-day moving average is $69.40 and its two-hundred day moving average is $75.63. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The company has a market cap of $3.31 billion, a P/E ratio of 25.92, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.